

DISCLAIMER

The following provisions apply to this presentation. Please consider its contents carefully.

Currency of information

The information contained in this presentation is current as at the date of this presentation or such earlier date as specified in this presentation.

Summary information

The information in this presentation is of a general nature only. It does not purport to be complete.

Not investment advice

The information contained in this presentation is not investment or financial product advice or any recommendation to acquire securities in McPherson's Limited (ASX: MCP). This presentation has been prepared without taking into account your investment objectives, financial situation or particular needs.

Company information

MCP's historical information in this presentation is, or is based on, information that has been released to ASX. This presentation should be read in conjunction with MCP's other periodic and continuous disclosure information lodged with ASX, which are available at www2.asx.com.au.

Third party information

Certain market and industry data used in connection with this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither MCP nor any of its related bodies corporate, directors, employees, agents or advisers have independently verified such market or industry data.

Historical information

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as, and is not, an indication of future performance.

Forward looking information

This presentation contains certain forward-looking statements that involve risks and uncertainties. MCP can give no assurance that these expectations will prove to be correct. You are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from those anticipated in these forward-looking statements due to many important factors, risks and uncertainties including, without limitation, risks associated with future capital needs, general economic uncertainty and other risks detailed from time to time in MCP's announcements to ASX. MCP does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws.

Disclaimer

No representation or warranty, whether express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. You should carry out your own investigations and analysis of MCP and verify the accuracy, reliability and completeness of the information contained in this presentation.

Neither MCP nor any of its related bodies corporate, directors, employees, agents and advisers accept any responsibility for any loss arising from anyone acting or refraining from acting in reliance on the contents of this presentation.

AGENDA



1. MCPHERSON'S TODAY

Grant

2. STRATEGY & OPERATIONAL REVIEW UPDATE

Grant

3. STRATEGIC GROWTH PLATFORMS

i. Core 6 brands, Key Channels

ii. Health Dawn

iii. International Expansion

David, Jade & TCG

Donna & Lori

4. OUR UNIQUE CAPABILITIES

i. Customer & Shopper education

ii. R&D / Innovation

iii. Sustainability

iv. Supply Chain

Lori

Donna

Donna

Paul

5. FINANCIAL UPDATE

Paul

6. SUMMARY & Q&A

Grant



MCPHERSON'S - AT A GLANCE

FY21 Forecast Revenue \$200 - 205M

340+ Staff 40% Customer facing **1,625** SKU's² 5 No.1 Brands 13 Categories³





1.2M Points of Distribution Globally



Countries



11,000+ Customer Stores

+50%1

of Australian households purchased an MCP brand in the last 12 months

¹ IRI Shopper Panel Data MAT 31/1/21 (Multix 50.2%; Manicare 10.2%; Lady Jayne 3.8%; Dr LeWinns 1% HH penetration)

^{2.} MCP Saleable SKU's, A,B, C & N Saleable on the 19th May '21

^{3.} Categories. Australian IRI Categories MCP competes in.

HEALTH, WELLNESS & BEAUTY - A STRONG FUTURE

WE'RE OPERATING IN A \$15.2 BILLION MARKET

HEALTH & WELLNESS¹ (\$7.5 Billion, +5.7% vs Year Ago)

BEAUTY¹ (\$7.7 Billion, +4.6% vs Year Ago)



NATURAL HEALTH

Immunity & Protection
Sleep & Mood
Joint & Movement
Digestive Health











HEALTHY SKIN & BEAUTY

Cosmeceutical
Australian Natural
Essential Beauty
Clean Beauty















HEALTH, WELLNESS & BEAUTY - A STRONG FUTURE

HEALTH & WELLNESS

BROAD
PENETRATION¹

78%

AUSTRALIAN'S PURCHASE COMPLEMENTARY MEDICINE

Past 12 months

AGEING POPULATION²

15% to 22%

Over 65 YRS 2017 Vs 2057

SIZE, STRENGTH, & GROWTH³ \$7.5B

AUSTRALIAN HEALTH & WELLNESS CATEGORY

COVID IMPACT₇

64%

GLOBAL CONSUMERS ARE FEARFUL FOR THEIR HEALTH

BEAUTY

MARKET POSITION⁴

MCP No. 2

AUSTRALIAN BEAUTY
SUPPLIER TO PHARMACY

CONSISTENT CATEGORY GROWTH⁵ +4.8%

GLOBAL BEAUTY INDUSTRY EST. 4YR CAGR to 2025

STRONG ANTI AGEING BEAUTY NEEDS⁶ 82% 9

93% 97%

CHINA USA

UK

TOP 2 BOX SURVEY RESULTS

1. Complementary Medicines Australia: Industry Audit & Trends 2020
2. Source: Older Australia at a glance; Australian Institute of Health & Welfare
3.IRI MarketEdge Pharmacy & Grocery
4.IRI market data: MAT FEB 21


5. Statista Beauty & Personal Care Worldwide Outlook 2021 to 2025 7

6. ADNA Consumer Research. Women 20 to 50yrs, 88% Strong Agree/Agree that they Like to prevent the signs of ageing on my skin China 88% (n=3,504), USA 93% (n=3,313), UK 97% (n=3,103) 7. Accenture Covid-19 Consumer Research, conducted April 2–6, 2021. Proportion of consumers that agree or significantly agree N= 3,074.

MCP - WINNING IN LARGE HW&B CATEGORIES

CATEGORY	Size	MCP Share
Vitamins Mineral Supplements	\$2B	<1%
Skincare	\$1.3B	2%
Haircare	\$794	<1%
Bags Wraps Foils	\$447M	28%
Beauty Accessories	\$189M	40%
Footcare	\$93M	6%
Hair Accessories	\$56M	35%
Cotton	\$48M	61%

MCP CATEGORIES: \$SIZE & GROWTH & AVG RETAIL PRICE





STRATEGIC INTENT

Health, Wellness and Beauty remains our core focus

Our near-term focus will be on the growth potential in existing categories from our established brands, capabilities, customers and channels Growth potential through greater collaboration, alignment and simplification of purpose, including a simplification of the JV strategy

Brand acquisitions consistent with this definition have been a key component of our transition and will continue to be assessed – but with clear guard rails

OPERATIONAL REVIEW OUTCOMES

TARGET \$300M SALES & \$50M EBIT IN FY26

6 CORE OWNED BRANDS & KEY CHANNELS

- Laser focus on realizing and leverage domestic market capabilities: strong brand positions, executional resources and relationships
- Drive growth by tapping into adjacent markets and R&D



- The unique" ancient wisdom and modern medicine" hybrid positioning resonating well with consumers
- Ranging upside in Australian Pharmacy and reset from zero in New Zealand
- NPD is a significant growth opportunity




- De-risking reliance on one brand, one channel, one geography in Export
- Leverage and build on key partnerships in Export, whilst keeping realism in expectations.



Amend overheads to reflect the "reset" level of profitability in F21

- Drive efficiencies in Supply Chain and Distribution
- Deliver procurement and component price opportunities
- Reduction in overheads while preserving the core capabilities that drive our proposition

A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas:



Greater opportunity in the domestic market than previously appreciated:

- Brand positions, executional resources and relationships are strongest.
- Opportunity to better leverage these capabilities to support sales opportunity via better ranging, customer and channel expansion
- And brand growth is expected to be greater via adjacency opportunity and greater focus on innovation.














THESE INITIATIVES ARE TARGETED TO DELIVER \$230M SALES & \$29M EBIT BY FY26

A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas



The acquisition process and the recent review of Global Therapeutics has driven a sound understanding of the opportunities in this space

- The unique "ancient wisdom and modern medicine" hybrid positioning resonates well with consumers
- Ranging upside is significant in Australian Pharmacy and will be reset in New Zealand
- A significant growth opportunity exists through acceleration of new product development (NPD)





THESE INITIATIVES ARE TARGETED TO DELIVER \$30M SALES & \$7M EBIT BY FY26

A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas




Build on the established success of Dr LeWinn's in China - de-risking reliance on one brand, one channel, one geography in international

- Continue to leverage and build on key partnerships, whilst keeping realism in expectations
- Renewed ranging and support for Dr LeWinn's will increase the breadth of distribution points beyond current levels
- Selectively use Cross Border E-Commerce (CBEC) into other large markets of relevance
- We are progressing non China markets and will leverage for other portfolio brands of relevance



THESE INITIATIVES ARE TARGETED TO DELIVER \$40M SALES & \$8M EBIT BY FY26

A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas



We will amend overheads to reflect the "reset" level of profitability in FY21

- Efficiencies will be gained in Supply Chain and Distribution, as we consolidate businesses acquired and optimise
- We will deliver procurement and component price opportunities for formulated brands of scale that are material
- Overheads will be addressed while preserving the core capabilities that drive our proposition

THESE INITIATIVES ARE TARGETED TO DELIVER \$6M EBIT BY FY23

STRATEGIC & OPERATIONAL REVIEW TARGETS

COST EFFICIENCY AND COST BASE AMENDMENTS PROGRAM

Full Year EBIT impact rises from ~\$3M in FY22 to ~\$6M in FY23

- Warehouse Efficiencies programmed efficiencies evolving to ~\$0.8M in FY23 with immediate capture of \$0.4M in FY22
- Delivery Optimisation evolving from \$0.6M in FY22 to \$1.0M in FY23
- 3. Procurement and product cost formulation (COGS reduction) \$1.0M in FY23
- 4. Selling, General and Administrative (SG&A) cost improvements of \$2.2M in FY22 evolving to \$3.2M in FY23

(\$M)	FY22	FY23	Annualised Cost Efficiencies
Warehouse	\$0.4	\$0.4	\$0.8
Delivery	\$0.6	\$0.4	\$1.0
COGS Reduction	\$0.0	\$1.0	\$1.0
SG&A	\$2.2	\$1.0	\$3.2
Total	\$3.2	\$2.8	\$6.0

STRATEGIC & OPERATIONAL REVIEW TARGETS

Confidence in growth

We anticipate FY26 sales of \$300M and EBIT of \$50M

Clear building blocks

Sequenced deliverables to illustrate the pathway to this performance outcome


Enhanced capability

Preservation of core value drivers, but in concert with cost optimisation delivery

Better performance expectation

Leading to a better performance expectation in a lower risk environment





STRATEGIC PRIORITY 1

6 CORE OWNED BRANDS & KEY CHANNELS

MARKET LEADING BRANDS WITH HEALTHY BRAND METRICS



STRATEGIC PRIORITY 1



#1 Australian Cosmeceutical
Brand
TOP 10 FACIAL SKINCARE
PHARMACY



#1 Hair Tools & Accessories +1.9 SHARE POINTS PHARMACY & GROCERY



#2 Natural Haircare in Pharmacy +1.6 SHARE POINTS PHARMACY & WOOLWORTHS



#1 Sustainable Wraps & Foil #1 Foil, Bake, Garbage & Freezer Bags



#1 Beauty Tools & Accessories +2.2 SHARE POINTS PHARMACY & GROCERY



#1 Cotton +2.6 SHARE POINTS PHARMACY & GROCERY

Source: Data sourced from IRI MarketEdge based on data definitions provided by McPherson's Consumer Products. Australian Pharmacy & Grocery Weighted Market. Beauty Accessories MAT 14/03/2021, Hair Accessories Category MAT 11/04/2021; Cotton, Facial Skincare, Haircare, BWF category MAT 28/03/21

CORE BRANDS: 5 YEAR VISION



STRATEGIC PRIORITY 1



Drive market share gains in pharmacy through inner and outer beauty innovation TOP 3 FACIAL SKINCARE



Connect with consumers through style innovation and grocery channel expansion 39% SHARE (+4.0%)



Build scale through channel expansion and efficacious natural credentials +102% GROWTH



Lead and partner with retail customers to drive sustainable transformation 36% SHARE (+7.3%)



Lead category growth through real estate & salon at home innovation 32% SHARE (+2.7%)



Drive cotton leadership and expand equity into adjacent categories
+\$6.2M RETAIL SALES GROWTH

INNOVATIVE SKINCARE RESONATING WITH CONSUMERS



DR. LEWINN'S

Strong track record for successful new product launches to drive share gains

- New Marine Collagen Liquid Shots ranked within Top 5 Facial Skincare NPD in the latest Quarter
- Within Chemist Warehouse Marine Collagen Liquid Shots ranking #5
 in Dr. LeWinn's range since launch in February
- New potent Eye Serum launched in China leading up to 6.6 Festival and major Domestic activation planned in November 2021
- Renovation of core ranges with increased clinicals 2022
- 34 Dr. LeWinn's R&D projects in the pipeline









HIGH PERFORMANCE NATURAL SKINCARE AND HAIRCARE



A'KIN

Boosting clinical claims to build scale in pharmacy and grocery

- 31 clinically proven products within A'kin range
 - Clinically proven A'kin Hair Mask contributing 10% to A'kin Haircare range
 - Clinically proven A'kin Deodorant increasing year on year +139%
- Build scale and awareness to drive consumer penetration
 - Grocery expansion across haircare, skincare and personal care
 - Invest in new brand campaign "Approved by Nature, Clinically Proven"
 - Evolve packaging and new products in line with clean beauty macro trend







LEVERAGING MACRO TRENDS TO DRIVE CATEGORY GROWTH



MANICARE

\$68M¹ masterbrand connecting through beauty at home macro trend

- Continued investment in merchandising real estate and on-line to engage consumers across all path to purchase touch points
- Focus on skincare beauty tools segment growing +37% to drive increased brand penetration and higher value purchases
- New lash technologies year on year driving increased consumer demand
- Partnering with retailers to bring affordable technology innovations to the mass market









CONSUMER LED INNOVATION DRIVING DOUBLE DIGIT GROWTH





LADY JAYNE

Increasing leadership through accessible styling across channels

- Covid accelerating category growth (+16%) with Lady Jayne leading the charge (+23%) through innovation and high social reach (6.7M)
- Expansion in grocery represents \$3M incremental retail sales opportunity
- Leverage leadership in hair brush innovations as the entry point into grocery
- Target high value hair accessories with fast fashion NPD via expert panel and runway trends









LADY JAYNE* x SIR.

STRENGTHENING OUR COMMITMENT TO SUSTAINABILITY



MULTIX

Transforming the category with sustainable products

- Continue to drive Multix as the consumer brand of choice to expand distribution:
 - 50.2% household penetration for Multix brand
 - 79% of sustainable buyers buy Multix Greener
- Upsize packs to support sustainability ranges as the everyday norm
- Lead sustainable innovations to protect future generations





















INCREASING SUSTAINABLE FOOTPRINT THROUGH PARTNERSHIPS



SWISSPERS

Trust, quality and care for the planet

- Covid shift towards trusted brands saw Swisspers achieve 61% share high in the cotton category
- Swisspers expanded sustainable range with 5 cotton tip paper stem products and 6 Eco Biodegradable Wipes launched in the last 12 months
- Continued drive for sustainable, locally sourced cotton enhancements
- Partnering with retailers with plastic reduction initiatives:
 - 562M plastic cotton tips eliminated in supermarkets since change over to paper stems









TARGETED ADJACENCIES TO WIN AND EXPAND OUR EQUITY

STRATEGIC PRIORITY 1



- Manicare expansion into Power Beauty Tools targeting mass channels at affordable price points
- Leverage salon at home beauty trend with clinically proven facial and body tools
- High retail price points \$50 to \$130 drives category value
- Quality, trust and efficacy to target +2.7 share point gains



- Swisspers equity expansion into high growth Baby category
- Baby Needs segment growing +20%
- Target \$3.5M Swisspers Baby Cotton milk range
- 65% of parents are willing to pay more for products that contain Natural plant ingredients.





- Transformation of Stratton from a small, bottom shelf product to a proud Men's Grooming brand. Target \$2.2M retail sales
- Targeting everyday grooming and high demand Beard care









- Sugarbaby refresh targets \$42M¹ pharmacy tanning category
- Gen Z² focused brand 5 million Australians, on average spent \$448 on cosmetics and skincare in 2020
- Consumers opting for in-home beauty and skin treatment following COVID19
- Beauty e-commerce³ grew 76% v
 YA driven by 'skinfluencers'

POSITIONED FOR GROWTH





TOTAL DISTRIBUTION POINTS IN ANZ BEAUTY



MCP Field and Customer Service Team call on >7,000 Australian & New Zealand Pharmacy and Independent Grocery outlets

RESPONDING TO SHOPPER BEHAVIOUR SHIFTS FY21

Pivot to online



INCREMENTAL RANGING

+ 1,355

INCREMENTAL ONLINE DISTRIBUTION POINTS

INVESTMENT

+ 30%

INVESTMENT IN MAJOR
CUSTOMER ONLINE PLATFORMS v
FY20

In store engagement

53%1

SHOPPERS CHANGE MIND IN STORE

OFF LOCATIONS

+ 39%

INVESTMENT

EDUCATION & RECOMMENDATION

30

EDUCATION BASED ACTIVATIONS
IN PHARMACY

INVESTMENT IN SHOPPER FY22



Engaging shoppers in their path to purchase



INVESTMENT

+22% investment online & social vehicles



POINT OF PURCHASE

+23% spend in off locations v FY21 Continued investment in category solutions



EDUCATION & RECOMMENDATION

38 education based activations in Pharmacy

STRATEGIC PARTNERSHIPS




1. RSV = Retail Sales Value



ANZ 5 YEAR GROWTH DRIVERS





TOTAL ANZ: KEY DELIVERABLES & TARGETS



 \bullet Base ANZ Business includes Singapore & excludes the Health Division SALES FY21 - FY26 Target



STRATEGIC PRIORITY 2

HEALTH AND WELLNESS A NEW GROWTH PLATFORM

HEALTH & WELLNESS: A NEW GROWTH PLATFORM



STRATEGIC PRIORITY 2



Enter in to the health and wellness category and provide a new platform for growth



DELIVERABLES

- Acquired Global Therapeutics to form McPherson's Health Division
- 71% of the Health team have a Health qualification
- Regulatory and innovation capability
- Fusion Health brand strong resonance with consumers

Product and market expansion



- Global category valued at over US\$50B1
- Australian vitamin & dietary supplement category AUD\$3.9B2
- Growth plan for the international and domestic markets
- New product development focused on fast growth segments

Ability to leverage across platforms and generate operating efficiencies



- Strong supply chain focus
- Health qualified team now driving Happy Flora and Soulful
- Operational efficiencies in distribution
- Leverage capability in international markets

^{1.} Statista: Size of the vitamin supplement market worldwide 2019

^{2.} Complementary Medicines Australia: Industry Audit and Trends 2020

MCP HEALTH BRANDS A KEY GROWTH PILLAR



Momentum building...

- Inventory and in-stock position strongest since February 2019
- April '21 strongest sales month since September '19 (Excluding March '20 COVID-19 impact)
- Focused retailer and consumer campaigns
- Operational review kick started 5 year strategic growth plan
- Health capability transitioned into McPherson's



TRANSITION TO MCPHERSON'S HEALTH



STRATEGIC PRIORITY 2

Successfully transitioned into McPherson's warehousing and IT systems in March

- April 2021 go live, McPherson's Health full transition
- Products currently manufactured by Blackmores moving to an Australian contract manufacturer as per acquisition requirement
- Q4 FY21 Health Division commenced selling A'kin and JV brand Happy Flora into the health food channel
- Warehouse efficiencies & delivery optimisation captured in supply chain cost based amendments program



HERBAL & TRADITIONAL PRODUCTS A HIGH GROWTH SUB SEGMENT



78%¹ of Australians have purchased at least one form of complementary medicine in the last year

83%¹ of
Australian women
have purchased at
least one form of
complementary
medicine in the last
year

1 of 3¹ Australians using complementary medicines to manage symptoms of chronic pain

52%² herbal, traditional or complementary supplements consumed daily

\$3.9B VITAMINS / NATURAL HEALTH CATEGORY¹



Australian complementary medicines

55%¹
2014/2019
CAGR

Herbal & Traditional Products

57%¹
2014/2019
CAGR

2. T-garage Consumer Research: Fusion Health brand and category exploration Feb '21

^{1.} Complementary Medicines Australia: Industry Audit and Trends 2020

CONSUMER INSIGHTS VALIDATE FUSION'S UNIQUE & STRONG BRAND POSITIONING



STRATEGIC PRIORITY 2

On initial exposure the Fusion Health brand appears modern and credible with clear cues to nature, eastern philosophies and current scientific approaches

Red palette

Strong cues to Chinese medicine principles or ingredients

Ancient wisdom

Suggests roots in Chinese medicine. Respected and believable



Yin and Yang

Suggests balance between old and new or East and West

Planticonography

Natural, herbal, plant-based products

Modern medicine

Safe, reassuring, underpinned by science, rigorous testing

Fusion

Modern terminology, scientific, on trend (heard a lot in cooking) feels both exciting and safe

FOUR CORE PILLARS - TARGETING \$30M IN SALES BY 2026



1

Pharmacy Growth /
Improve Core Range
Compliance

2

New Zealand & eCommerce

3

New Product Development

4

Health Food & Brand Opportunities

- Double pharmacy distribution
- · Improve 'shopability'
- Merchandising solution
- Create destination


Refresh and relaunch NZ

- New Market Singapore eCommerce
- Grow eCommerce through customer partnerships


- Ideation plan developed
- Collaboration with ingredient experts exploring new opportunities

- Grow Health Food share
- Targeted investment driving core brands
- Education solutions enabling quality consumer experience
- Represent all MCP health focused products in market

HEALTH & WELLNESS DIVISION TARGETING \$30M BY FY26



SALES FY21 & TARGET FY26




STRATEGIC PRIORITY 3

EXPAND INTERNATIONAL FOOTPRINT

EXPAND OUR INTERNATIONAL FOOTPRINT




REBALANCING INTERNATIONAL GROWTH



ii. MCP SKIN CARE & HEALTH PORTFOLIO (\$M)

INCREMENTAL SALES: FY21 TO FY26 TARGET





USA - WIN WITH DR. LEWINN'S VIA ONLINE



By FY26 target USA as 3RD largest Dr LeWinn's market outside Australia & China

MARKET INSIGHT

DRL

STRENGTH

STRATEGY

SIZE

USD\$30B1

Skin care market ('21) Growing at 3.7%

PURCHASE INTENT

71%4

Top 2 Box Purchase Intent - Dr LeWinn's Triple Action Day Defense Anti-Ageing Serum

ONLINE TO OFFLINE

amazon

In FY22 target the \$1.3bill in retail sales of skincare, driving share gains

STRENGTH

42%²

Shop online for beauty (Top 3 channel), with online share forecast to reach 48% by '23.

BRAND APPEAL

15%⁴

Top Box "Very Appealing score"

DRL USA consumer research

BEAUTY E-COMMERCE PLATFORMS

TARGET 3

Top 10 Beauty E-Commerce platforms to expand penetration by FY23

MARKET SITUATION

86%³

Beauty sales online not from the Top 20 manufacturers

CONSUMER NEEDS

Anti-Ageing⁵

57% claim as Top functional need Females 30 to 50

SPECIALTY RETAIL DOORS

TARGET 250

By FY24 specialty retail doors over the next 2-3 years from Sephora, ULTA Beauty or Bath & Body Works

^{1.} Statista 2021 USA Skincare Retail Sales Value

^{2&}amp;3. NPD Online sales of prestige beauty -19th Nov '20

UK & EU- PACED ROLLOUT FOR DR. LEWINN'S



MARKET

INSIGHT

CHANNEL OPPORTUNITY

CONSUMER INSIGHT

UK

US\$3.9B

Skin care market ('21) Statista

GERMANY

US\$4.6B

Skin care market ('21) Statista

FRANCE

US\$4.0B

Skin care market ('21) Statista

UK E-COMMERCE

41%

prestige skincare sales in (Jan-Oct), growing at +54% Vs YA.

* NPD Online sales of prestige beauty -19th Nov '20

UK PARTNER

Online partner

Specialist online platform partner identified. Commercial terms commenced

RUSSIA

69%

Russian female consumers plan to continue buying cosmetics online

Miguel Agency Russia Survey 2020

PURCHASE INTENT

43%

Top 2 Box Purchase Intent - Dr LeWinn's Triple Action Day Defence Anti-Ageing Serum*

POSITIVE APPEAL

33%

Consumers find Dr LeWinn's very appealing when viewed video for the first time*

TREND

UK. FR. GER Sign of recovery

+33%

UK total prestige beauty increase 1st half 2020 * NPD Group 2021

Online survey of 3103 20 - 50yr old women across UK from 24th to 27th April 2021

Strategy

Top 5 online beauty platform, delivering 500 brands and 30,000 products

FEELUNIQUE



- Target a further 2 out of the Top 10 Beauty E-Commerce platforms to expand penetration.
- Launch in Top 200 specialty retail doors from Boots (2,336 UK doors) or Waitrose & Partners (335 doors)

lookfantastic



WAITROSE



FY25

- Paced European market expansion 1 market/year
- Penetrating key local retailers and e-comm platforms



By FY26 Dr LeWinns for UK & Europe is targeted to be the 4th largest region (sales revenue) for Dr LeWinn's after Australia, China & the USA

EXPAND ASIA & MENA* SKINCARE BRANDS WITH EXISTING PARTNERS



MARKET INSIGHT

)

CHANNEL OPPORTUNITY

CONSUMER INSIGHT SIZE

\$235B¹

ASIA/MENA MARKET SIZE 2021

Beauty & Personal Care

GROWTH

+8.5%2

MENA Beauty & Personal care set to grow twice as fast as global ('21 to '26)

GDP

ASEAN-63

Increasing share of global GDP and forecast to increase post COVID

ASIA

+55%4

Of consumers claim they will permanently change their online shopping behavior

MENA

19.5%

to 30.2%⁵

User penetration 2021-2025

E-COMMERCE

60%⁶

of Dr LeWinn's & A'Kin FY21 forecast sales are expected to come from E-Commerce

DEMAND FOR NATURAL

>50%7

of consumers in Singapore look for products that are parabenfree, cruelty-free, natural, fragrance-free and sls-free **ANTI AGEING**

98%8

of consumers in Singapore look to prevent the signs of ageing on their skin **TREND**

80%9

of consumers would continue to shop online after covid lockdown (Singapore)

Strategy

KEY GROWTH MARKETS

Vietnam

Highest growth in skin care in Asia (ex – China & Australia)

Malaysia

- 2nd highest growth in skin care in Asia
- · Neighbours Singapore provides economies of scale

Gulf Cooperation Council (GCC)

 Distributors aligned with growth opportunity for Dr LeWinn's across GCC

KEY RETAILERS FY22

Accelerate penetration in Top 5 beauty platforms









Target top 300: Watsons stores (6,300 stores, 11 countries) or Guardian stores (715 stores) for Dr LeWinn's & Akin core ranging



watsons

^{1.&}amp;2. Statista 2021 Outlook - personal care / ecommerce Asia & United Arab Emirates

^{3.} IMF, Macrobond, Bloomberg, ANZ Research

^{4.} Euromonitor International COVID-19 Voice of the industry survey Arpil-2020

^{6.} Internal MCP Expansion Forecast

DR. LEWINN'S - A STRONG BRAND IN CHINA



\$A80M¹
underlying brand value
in the hands of the
Chinese consumer

Despite challenging market conditions YTD demand in China remains stable at -2%³ in value

9% of Chinese female respondents found Dr. LeWinn's very appealing as a brand²

CBEC remains strategically important for Dr. LeWinn's growth in China

THE FUTURE

Exclusive partnership

- Measurable returns from a growing channel
- Direct engagement with resellers as brand advocates

Strengthening of Partnership

- Building the consumer base
- Expanding sales opportunities within the relationship model

Elevating Marketing Activation

- New marketing platforms and media
- Expanded marketing support for the brand

New Partnerships TCG GROUP

Engaging in new relationships with expertise to support our existing partners in driving expansion

^{1.} Access Corporate Group Brand Team Sales Report FY21 YTD End March Dr. LeWinn's Volume & Value

^{2.} ADNA Research 3504 women asked in an online questionnaire in Tier 1 and Tier 2 cities, May 2021

^{3.} Access Corporate Group Internal Data as quoted in MCPASX Announcement 29th April, 2021

CHINA LANDSCAPE CONTINUOUSLY CHANGING



Strong Growth in China CBEC
Sales¹

Consistent growth between 2018 and 2021 in CBEC¹

Total ecommerce in China is expected to grow 44% by 2024²



Leverage strength in consumer demand in China

Dr. LeWinn's is playing in the right channel.

Opportunity to expand scope within ecommerce

".....it's unlikely that all of the...sales...that disappeared as the Daigou trade to China slumped will eventually return." 3

> "Brand AU" continues to face challenges requiring agility in approach



Dr. LeWinn's was sheltered from a bigger impact as a result of the exclusive ABM relationship

Brands must adapt to the changing market conditions and how they access and keep the attention of consumers

COVID-19 accelerated an ongoing trend of consumers in China shifting towards

online channels.4

The pandemic triggered a self-care, beauty & skincare boom in China



Brands must connect with the demands of the Chinese consumers and be direct in their marketing messages to leverage trends and keep up with the pace of the market



RAND ARCHITECTS

China Beauty Market worth 600B RMB by 2023.⁵

Anti Ageing represents nearly 3/4 of the skincare category in China and is growing +63% year on year.6



With the consumer base and demand for skincare in the CBEC space growing, the key is knowing how to connect with Chinese consumers in a meaningful way.

https://www.tmogroup.asia/tmos-2021-china-ecommerce-insights/

China Skinny 2021 Skincare & Beauty Tracker

Australian Financial Review, 22 April 2021

https://www.mckinsey.com/~/media/mckinsey/featured%20insights/china/china%20still%20the%20worlds%20growth%20engine%20after%20covid%2019/mckinsey%20chino%20consumer%20report%202021.pdf

China – Beaute Research Retail Panel – Skincare Growth Contributors

FUSION HEALTH CBEC OPPORTUNITY



Health Supplement market size expected to rise 280B RMB by 2023¹

CAGR forecasted at 14% between 2019 and 2023¹



Accelerate Local Market
Activation

Fusion Health opportunity as the demand grows for Health Supplements in China

Australia & USA leaders in Health Supplements for the China market.²

"Brand AU" dominates with 22.3% market share in cross border and social ecommerce. ²



Demand for Australian
Health Supplements has not declined.

This, despite the issues facing Australian brands in China.

Health Supplement purchase intent increased among Chinese consumers. ²

Increased health awareness since the pandemic has resulted in increased purchase intent for Health Supplements.²



Leverage growing consideration for health & safety

Building the marketing foundations in China will help connect Chinese consumers with Fusion Health

TCG GROUP

RAND ARCHITECTS

Traditional Supplements are most favoured.¹

Chinese online shoppers favour traditional and nutritional product types.¹




Driving High Conversion

Fusion Health offers a natural connection between use and ingredients for Chinese Consumers which can drive high conversions in online shopping

- ... https://www.tmogroup.asia/health-supplement-report-2020-chinese-market/
- Vitamin-and-Health-Supplements-market-in-China-report-by-daxue-consulting

INTERNATIONAL EXPANSION TARGETING \$40M BY FY26



USA

UK & EU

ASIA (EX CHINA) / MENA

FY21 FORECAST

SALES FY21 & Y26 TARGET

CHINA (DRL)

CHINA (EXCL DRL)

FY26 TARGET



EDUCATING OUR PEOPLE, CUSTOMER AND SHOPPER

SHOPPER

+58 how to videos

MCPHERSON'S ACADEMY

+200 active participants per month

QUALIFIED TRAINING TEAM

6 Qualified naturopaths
2 Qualified beauty advisors



3 M Views
How to tutorials



30
Education based activations



+2000 Retail assistants trained



14 Customer events




30 Internal training events



Source: Demio Training platform/MCP Academy/MCP coop investment tracker / You Tube and Vimeo

INNOVATION SUCCESS DRIVING SUSTAINABLE GROWTH





Foreign market registrations

- Australia
- India Thailand
- Japan
- UAE

- South Korea
- 7. Malaysia
- Singapore
- **Philippines**





EXPANSION INTO BEAUTY NUTRITION



#1 HAIR ACCESSORIES NPD



#1 NATURAL HAIRCARE SHAMPOO & CONDITIONER NPD



#1 COTTON SUSTAINABLE NPD

SUSTAINABILITY - OUR GOALS

OUR GOALS

MORE. LESS. NONE Sustainable Development. Reduced Environmental Footprint

SOURCE RESPONSIBLY

Reduce Operational Impact. Collaboration.
Transparency

PEOPLE & COMMUNITY

Sustainable Trusted Organisation. Improve Society

WHAT WE'LL DO

- Reduction in Total Greenhouse Gas Emissions with an aim to achieve net zero Scope 1 and 2 carbon emissions by 2030
- Reduce the amount of non-recyclable, non-reusable or non-compostable packaging in our products by at least 25% by 2025
- Implementation of the Australasian Recycling Label on at least 60% of our Core Owned and JV products by 2022
- Continue to drive a modern slavery management framework in line with Australian Modern Slavery Act
- Have full traceability or certification for critical ingredients and components by 2025

Become a certified B-Corp by 2025

Annually report on our performance against our stated commitments and goals

AD DRESSING UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS











GAIN EFFICIENCIES AND SAVINGS ACROSS SUPPLY CHAIN



EFFICIENCY



AVAILABLE CAPACITY

+40%

Significant headroom in pick line

SUPPLY CHAIN COSTS

\$7.5M hard savings

Last five years

TRUSTED PARTNERS

60% formulated product now at Aware

DAILY DELIVERIES

7,600+

1,600 Australian Postcodes

COVID RESPONSE

Top 150 SKUs COVID response

ADAPTING

8 OUT 20 IN (incl Health)

Exit and entry of Brands into MCP

STAFF RETENTION

80+

Tenure > 19 Years

ALTERNATE SUPPLY

88%

China based supply can be sourced from alternate country

MCP HEALTH

Confirmed supply MCP Health ex Blackmores facility



SALES & EBIT TARGET SUMMARY - 5 YEAR PLAN

	SALES (\$M)			UNDERLYING EBIT (\$M)	
	FY21	FY26	FY21	FY26	
All figures \$M	Forecast	Target	Forecast	Target	
Total Australian and NZ Business ¹	\$182	\$230		\$29	
Health & Wellness ²	\$10	\$30		\$7	
International ³	\$8	\$40		\$8	
Cost optimisation				\$6	
Total	\$200	\$300	\$10 - \$13	\$50	

[.] Total ANZ Business includes Singapore (base business only) & excludes the Health Division

^{2.} Health & Wellness = Fusion Health & Oriental Botanicals

Countries include China Dr Lewinn's, China other, USA, UK, Europe, Asia & Middle East/North Africa

STRONG BALANCE SHEET PRESENTS OPPORTUNITY

Strategic M&A

Management will continue to review strategic, complementary, EPS accretive M&A opportunities

Capital management initiatives

Capital Management initiatives put on hold throughout the bid process will be reconsidered

High dividend payout ratio

Current dividend policy is to pay a minimum of 60% of underlying NPAT subject to cash requirements

Return of high franking credits

Franking credits currently total ~\$25M

6. SUMMARY



STRATEGIC & OPERATIONAL REVIEW TARGETS



We anticipate FY26 sales of \$300M and EBIT of \$50M

Clear building blocks

Sequenced deliverables to illustrate the pathway to this performance outcome

Enhanced Capability

Preservation of core value drivers, but in concert with cost optimisation delivery

Better performance expectation

Leading to a better performance expectation in a lower risk environment

